This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Friday's Health Winners & Losers

Health care stocks were lower Friday, despite a $60 million deal and Corcept's (CORT) continued rise.

Boston Scientific (BSX) said Thursday after the market's close that it purchased technology for treating symptomatic benign prostatic hyperplasia, or enlarged prostate, from biotechnology company Celsion (CLN). The companies said the purchase regards primarily the Prolieve Thermodilatation System, for which Boston Scientific has been the exclusive distributor since 2004.

Columbia, Md.-based Celsion said Boston Scientific will pay $60 million for the Prolieve assets in three installments, $30 million at the closing of the deal and then $15 million on the first and second anniversaries of the closing. Celsion also said it repaid the principal and accrued interest on a $15 million promissory note due to Boston Scientific at closing.

Boston Scientific was down 23 cents, or 1.4%, to $15.78. Celsion fell 38 cents, or 5.4%, to $6.72.

Corcept Therapeutics shot up another 37 cents, or 21%, to $2.12 Friday, a day after the company bounded 23% after releasing positive proof-of-concept study results on weight-loss drug Corlux. Punk, Zeigel & Co. on Friday upgraded the stock to accumulate from market perform.

Medtronic (MDT) on Friday said that it launched a new physician component to its CareLink Therapy Management System for Diabetes. It also announced a new quarterly dividend of 12.5 cents a share for the company's common stock, a 14% increase compared to its prior quarterly dividend of 11 cents a share. The company said the dividend is payable on July 27 to shareholders of record at the close of business on July 6.

In addition, Medtronic is increasing its share repurchase plan by an additional 50 million shares of its common stock, raising the total to 60 million shares. The company said this represented 4.4% of its total common shares outstanding.

And finally, Medtronic elected David Calhoun and Ken Powell to its board of directors. Calhoun is chairman of the board and chief executive of The Nielsen Company. Powell is president, chief operating officer and director of General Mills (GIS).

Medtronic closed down 18 cents, or 0.4%, to $51.61.

Johnson and Johnson (JNJ) was also down just a bit Friday. On Thursday the company said it received an approvable letter from the Food and Drug Administration for schizophrenia drug Risperdal for adolescents. The letter didn't call for additional study data, just a bit of tinkering with the label, according to the company, which was down $1.38, or 2.2%, to $60.73.

Johnson and Johnson is part of the Amex Pharmaceutical Index, which was down 5.48, or 1.6%, to 344.60 on Friday.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs